Cargando…

The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea

BACKGROUND: The speed of adoption of new drugs and frequencies of substitutions leads to changes in health care expenditures as well as patient outcomes. In this study, we aim to understand the speed of adoption of new drugs and their prescription volume in health care institutions and evaluate the...

Descripción completa

Detalles Bibliográficos
Autor principal:	Son, Kyung-Bok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251874/ https://www.ncbi.nlm.nih.gov/pubmed/32460730 http://dx.doi.org/10.1186/s12889-020-08929-6

Ejemplares similares

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016
por: Ko, Young-Jin, et al.
Publicado: (2018)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care
por: Delesie, Michiel, et al.
Publicado: (2022)

Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals
por: Carlson, Josh, et al.
Publicado: (2009)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

The Effects of Prospective Reimbursement Programs on Hospital Adoption and Service Sharing
por: Cromwell, Jerry, et al.
Publicado: (1982)

The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada
por: McPhail, Melanie, et al.
Publicado: (2022)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
por: Kim, Dong-Sook, et al.
Publicado: (2021)

Effects of the Revised Reimbursement Guideline for Anti-Osteoporosis Medication in South Korea
por: Ko, Young-Seung, et al.
Publicado: (2022)

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Geriatric Conditions and Prescription of Vitamin K Antagonists vs. Direct Oral Anticoagulants Among Older Patients With Atrial Fibrillation: SAGE-AF
por: McManus, David D., et al.
Publicado: (2019)

Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
por: Petrusic, Tamara, et al.
Publicado: (2015)

Reimbursement of Digital Therapeutics: Future Perspectives in Korea
por: Ju, Jin Han, et al.
Publicado: (2022)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Understanding patient and physician responses to various cost-sharing programs for prescription drugs in South Korea: A multilevel analysis
por: Son, Kyung-Bok, et al.
Publicado: (2022)

Stakeholders’ Perceptions Regarding Digital Therapeutics Reimbursement in South Korea: Qualitative Study
por: Sim, Boram, et al.
Publicado: (2023)

Assessing potential prescription reimbursement changes: Estimated acquisition costs in Wisconsin
por: Kreling, David H.
Publicado: (1989)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database
por: Ko, Young-Jin, et al.
Publicado: (2019)

Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery
por: Manfredini, Mattia, et al.
Publicado: (2021)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

Leveraging reimbursement strategies to guide value-based adoption and utilization of medical AI
por: Venkatesh, Kaushik P., et al.
Publicado: (2022)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
por: Cullell, Natalia, et al.
Publicado: (2018)

Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants
por: Brinkmeier-Theofanopoulou, Maria, et al.
Publicado: (2018)

Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions
por: Johannesdottir, Sigrun Alba, et al.
Publicado: (2012)

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
por: Faraoni, David, et al.
Publicado: (2015)

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
por: Carles, Misericòrdia, et al.
Publicado: (2015)

Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes
por: Park, Joong Hyun, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ar62si86460p5et6b52c5clrvv